Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 7.28%
As of Monday, November 16, Oramed Pharmaceuticals Inc.’s ORMP share price has surged by 7.28%, which has investors questioning if this is right time to sell.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Cynthia McLaughlin
Cynthia McLaughlin
Michael Rose
| Share Statistics | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $155.2 | $421.5 | 27% |
|
| Shares Out (Mil) | 43.0 | 46.9 | 44% |
|
| Institutional Ownership | 55.5% | 82.0% | 37% |
|
| Float (Mil) | 28.1 | 49.2 | 34% |
|
| Beta | 1.28 | 0.68 | 74% |
|
| Avg Daily Volume (000s) | 183 | 347 | 43% |
|
| Price Change (52-week) |
43.1% | 49.3% | 86% |
|
| Growth | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (5.8%) | 6.4% | 8% |
|
| Net Income (5yr) | 37.3% | (1.3%) | 89% |
|
| EPS (5yr) | 31.4% | 15.1% | 83 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.0%) | (15.0%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | $145 | ($11) | 63% |
|
| EPS (TTM) | $3.504 | ($0.700) | 80% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($7) | 27% |
|
| Net Cash Flow (TTM) (Mil) | ($23) | $1 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | $98 | $331 | 22% |
|
| Valuation | ORMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.46 | 2.08 | 12% |
|
| P/E | 1.0 | 20.9 | 1% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | 0.0 | 1.1 | 1% |
|
| Ratios | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | 46.6% | (23.8%) | 99% |
|
| ROE | 53.4% | (24.2%) | 93% |
|
| Liabilities to Assets | 15.4% | 31.6% | 10% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 11/20/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 5.9% |
| +/- S&P 500: | -1.5 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors